Ketamine and Psychedelic Therapy in Philadelphia, PA

How to Find Ketamine Care and a Psychedelic Therapist in Philadelphia

The fastest way to get ketamine treatment near you in Philadelphia is not a clinic search at all. Mindbloom connects you with a licensed clinician online, who reviews your history, confirms whether treatment is a good fit, and, if approved, prescribes a guided at-home program. That answers the two questions most people are really asking, how to get ketamine and where to get it, without a waitlist or a drive into Center City.

Many people in Philadelphia begin by looking for a psychedelic therapist, psychedelic-assisted therapy, or psychedelics near them. Here the honest answer matters: outside of ketamine, guided psychedelic therapy using psilocybin or MDMA is not legally available in Pennsylvania. Ketamine is the one psychedelic-class treatment a clinician can legally prescribe and supervise today, and with Mindbloom that supervision, preparation, and integration happen from home.

If you would rather be treated in person, Philadelphia does have in-clinic ketamine providers, mostly concentrated in Center City and Fishtown, with additional options on the Main Line. The next section compares those in-clinic routes against at-home care so you can see the real tradeoffs in format, monitoring, and cost.

Your Ketamine and Psychedelic Therapy Options in Philadelphia

Ketamine therapy in Philadelphia comes in a few formats. They differ in where treatment happens, how it is supervised, and what it costs. Mindbloom is the at-home option; the others are in-clinic.

In-clinic infusions and injections mean traveling to an office, being monitored on site, and paying per visit, often across a standard series such as six infusions over three weeks. A Center City clinic advertises IV sessions from $350, and a Fishtown provider lists intramuscular sessions around $400 and infusions around $450.¹¹ ¹² Spravato can be a fit for treatment-resistant depression and is sometimes covered by insurance, but coverage is conditional: it depends on your plan, prior authorization, and meeting the FDA-approved criteria, and it still requires on-site monitoring at each visit.

With Mindbloom, the same clinician oversight happens remotely. You complete treatment at home on a clinician-guided schedule, with a trusted person acting as your treatment monitor, and pay a flat per-session rate inside a program rather than a per-infusion clinic fee.

What about psilocybin, MDMA, LSD, or ayahuasca? These are what many people picture when they search for psychedelic therapy, so it is worth being clear. None are legally available for therapy in Pennsylvania. MDMA-assisted therapy is not FDA-approved, psilocybin service centers exist only in states with licensed programs such as Oregon and Colorado, and ayahuasca and LSD are not available as supervised treatments here. Ketamine is the psychedelic-class therapy you can legally begin in Philadelphia now. On the evidence, that is a strong place to be: Mindbloom's reported depression response (56.6%) is at or above the rate reported in the largest controlled trials of single-dose psilocybin for depression (about 37 to 42%), on a far larger published evidence base and delivered at home rather than in a full-day, in-person licensed-center session.¹ ⁸

Conditions Ketamine Therapy Can Address

Depression is the condition ketamine therapy is best known for, and it is Mindbloom's flagship focus. If you are looking for ketamine treatment for depression near you in Philadelphia, that is the core of the program: a structured course designed to lift depressive symptoms, often with initial relief early and benefit that builds over the full program.

Beyond depression, Mindbloom supports anxiety, PTSD, prolonged grief, burnout, and sleep difficulties. People searching for psychedelic treatment for PTSD near them are a good example: Mindbloom is the only at-home ketamine provider with peer-reviewed PTSD outcomes, so that interest has real evidence behind it. Ketamine therapy is not a fit for every condition, and Mindbloom deliberately focuses on what its own published data supports rather than stretching into claims it cannot back.

Mindbloom's Psychedelic Therapy Programs and Outcomes

Mindbloom is one of the largest at-home psychedelic-therapy providers, with more than 800,000 guided at-home sessions delivered. The outcomes below draw on Mindbloom's peer-reviewed subcutaneous study, which measured depression, anxiety, and PTSD in a single study. Mindbloom also has two earlier peer-reviewed studies of its sublingual protocol and research preprints extending the evidence to grief, burnout, and sleep, the largest published evidence base in at-home ketamine therapy. Individual results vary.

_{¹ Subcutaneous, six-session course (Parks AC et al. J Med Internet Res. 2026). Response = ≥50% reduction (PHQ-9/GAD-7) or ≥10-pt (PCL-5); remission = final PHQ-9/GAD-7 <5, or ≥10-pt reduction and PCL-5 <33.
² Swain et al. 2026 (grief, PGD-13), n=503. ³ Swain et al. (burnout, MBI-GS), n=395. ⁴ Swain et al. 2026 (sleep, PHQ-9 Item 3), n=13,963; single-item measure, ketamine is off-label for sleep.
ᵃ Grief remission = no longer met diagnostic criteria (71.1% DSM-5-TR). ᵇ Burnout response = improved on ≥1 dimension (69.6%); remission = fell below the burnout threshold (59.5%). ᶜ Sleep remission = complete resolution (score 0).}

Mindbloom offers tailored psychedelic-therapy programs, built with mental-health thought leaders, that use the psychedelic modality to address specific outcomes rather than only prescribing medication for them. Programs include Grief, Habit Change, Anxiety, Depression, Self-Love, and Burnout.

How those outcomes compare, each against a specific published study rather than a whole field:

• Mindbloom's reported depression response rate is roughly 38% higher than the rate reported in a study of psychotherapy for depression (56.6% vs ~41%), and reached faster.¹ ⁵
• Mindbloom's reported PTSD response rate is about 32% higher than the rate reported in a study of first-line SSRIs (76.7% vs 58%).¹ ⁶
• Mindbloom's reported at-home PTSD response rate exceeds the rate reported in the leading repeated-infusion IV ketamine trial (76.7% vs 67%).¹ ⁷

Is Ketamine Legal in Pennsylvania? What About Psilocybin and MDMA?

Yes, ketamine therapy is legal in Pennsylvania. Ketamine is a federal Schedule III medication that a licensed clinician can prescribe, including for off-label psychiatric use, and it is available in Philadelphia now through telehealth. Spravato, an FDA-approved esketamine nasal spray for treatment-resistant depression, is also legal and runs under an FDA safety program.¹⁰

Psilocybin and MDMA are a different story. Both are Schedule I under Pennsylvania law, and no Pennsylvania city, Philadelphia included, has passed a decriminalization or deprioritization measure. You may see claims online that Philadelphia has decriminalized certain psychedelics; that is not accurate. A state research bill for psilocybin therapy, HB 1959, has been introduced but has not become law.¹⁰ Until that changes, ketamine is the psychedelic-class therapy Philadelphians can legally start, and with Mindbloom you can start it from home. That momentum is now federal too: an April 2026 executive order directed the FDA and DEA to speed research and access for psychedelic treatments, with ketamine singled out as the one already available under medical supervision.¹³

How At-Home Ketamine Therapy Works With Mindbloom

Everything begins with an online clinical evaluation. A licensed clinician reviews your mental and physical health history and decides whether ketamine therapy is appropriate for you. Treatment is available to eligible adults after that evaluation, not on demand, because ketamine is a prescription medical treatment rather than a retail product.

If you are approved, your clinician prescribes a program on a clinician-guided schedule, and Mindbloom ships your medication and a guided kit. You complete each session at home with a trusted treatment monitor present, following the preparation and integration steps built into your program. Sessions are supported by the Mindbloom app and check-ins, so you are never doing this alone even though you are not in a clinic.

On safety: ketamine therapy has a well-established safety profile when it is properly screened and clinically supervised, which is exactly what the evaluation, the monitor requirement, and ongoing clinician oversight are for. Many clients feel some relief early in the program, with benefits accumulating over the full course rather than arriving all at once.

Cost, Insurance, and Working With Your Therapist

Mindbloom is self-pay, structured as a program rather than a per-visit clinic bill. Sessions work out to $165 to $215 each depending on the program you choose, and many clients use HSA or FSA funds. Some plans offer partial out-of-network reimbursement, and Mindbloom can provide documentation to support a claim, though coverage is never guaranteed. Compared with in-clinic infusions in Philadelphia that run from about $350 to $450+ per visit, the at-home program is generally the more affordable route.¹¹ ¹²

Ketamine therapy also works well alongside talk therapy. If you already see a therapist or psychiatrist in the Philadelphia area, Mindbloom's program is designed to complement that care, not replace it, and many clients find the two reinforce each other. If you do not have a therapist, the program's built-in preparation and integration still give each session structure and follow-through.

Ketamine and Psychedelic Therapy Across the Philadelphia Area

Because Mindbloom is delivered by telehealth, at-home ketamine therapy is available throughout the Philadelphia metro, not just in the neighborhoods where in-clinic providers happen to cluster. That includes Center City, Rittenhouse, and Fishtown within the city, and the surrounding suburbs across Montgomery, Delaware, Bucks, and Chester counties.

Residents of Main Line communities such as Bala Cynwyd, Ardmore, and Bryn Mawr, along with King of Prussia, Conshohocken, Media, West Chester, and Doylestown, can all start the same program from home. Wherever you are in the Philadelphia area, the path is the same: eligibility begins with an online clinician evaluation, then a clinician-guided program if it is a good fit for you.